Middle East Tapentadol Market to expand at a meteoric CAGR of 6.1 % by 2025
Tapentadol – Become Pain Free!
Tapentadol is an opioid pain medication, which is used to treat moderate to severe pain. Tapentadol is also indicated for neuropathic pain associated with diabetic peripheral neuropathy. It is typically used to treat chronic, acute, and cancer-related pain among patients and is legally available on prescription. Nucynta ER is the first and only U.S. FDA-approved long-acting opioid analgesic designed to control both, nociceptive pain, and neuropathic pain associated with diabetic peripheral neuropathy.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1054
Nucynta is available as Palexia outside the U.S. territory. Nucynta ER is contraindicated for patients suffering from significant respiratory depression, known or suspected gastrointestinal obstruction, acute or severe bronchial asthma or hypercarbia, including paralytic ileus, concurrent use of monoamine oxidase inhibitors (MAOIs), and Hypersensitivity (e.g. anaphylaxis, angioedema) to tapentadol or to any other ingredients of the product or use of MAOIs within a period of 14 days.
Market Dynamics-
Growing occurrence of cancer and diabetic neuropathy in the Middle East is expected to fuel growth of the Middle East tapentadol market
Increasing incidence of cancer and diabetic neuropathy in the Middle East is expected to drive growth of the Middle East tapentadol market during the forecast period. According to data published in World Journal of Diabetes in 2016, the Middle Eastern and North African regions are estimated to have the second-highest rate of diabetes in the world, in turn, increasing prevalence of neuropathic pain. According to World Journal Diabetes, in 2016, the prevalence of diabetes is projected to increase to 96.2% by 2035 in Middle East. Furthermore, according to the World Health Organization (WHO), the Eastern Mediterranean region, including Middle East, recorded 555,318 new cases of cancer in 2012, which is projected to rise to 961,098 by 2030. Thus, determining that the Eastern Mediterranean region is expected to have the highest relative increase of cancer cases among all regions in the world. According to Journal of Taibah University Medical Sciences, 2016, the number of people suffering from diabetic neuropathic pain in countries of the Middle East were as follows:
Quick Buy – Middle East Tapentadol Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1054
The Middle East tapentadol market was valued at US$ 0.82 million in 2016 and is expected to witness a robust CAGR of 6.1% over the forecast period (2017-2025).
Figure 1. Tapentadol related important events since discovery
Absence of gold standard opioid therapy for neuropathic pain other than tapentadol is expected to fuel the Middle East tapentadol market growth
The primary reason behind neuropathic pain is dysfunction of lesion to the central or peripheral nervous system. Moreover, it is chronic in nature with a complex pathophysiology. Generally, NUCYNTA ER (tapentadol) is used in the treatment of neuropathic pain the pain is severe enough to require tapentadol daily, whereas it is also used in long-term opioid treatment for which alternative treatment options are inadequate. There is low quality evidence that the oral tramadol has any important beneficial effect on pain for people suffering from severe or moderate neuropathic pain, whereas the main indication of tapentadol is to treat the diabetic neuropathic pain. This proves that other opioids such as fentanyl, oxycodone, tramadol, and oxymorphone are not as effective as tapentadol in the treatment of neuropathic pain.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/middle-east-tapentadol-market-to-surpass-us-146-million-threshold-by-2025-469
The U.S. Food & Drug Administration (FDA) tapentadol approval timeline
Competitive Landscape
Major players operating in the Middle East tapentadol market are Depomed, Inc., Janssen Pharmaceutical, Inc., Grünenthal, and Allergan Plc.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapeutic Application
- Market Snippet, By Countries
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- History Of Tapentadol
- Comparison with substitute
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- PEST Analysis
- Impact Analysis
- Industry Trend
- Epidemiology
- PORTER’s Five Forces Analysis
- Ongoing Clinical Trials
- Regulatory Scenario
- Reimbursement Policies
- Middle East Tapentadol Market, By Therapeutic Application, 2015 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2025 (%)
- Y-o-Y Growth Analysis, 2016 – 2025
- Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Neuropathic Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Cancer Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Neuropathic Pain
- Cough Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Introduction
- Middle East Tapentadol Market, By Countries, 2015 – 2025 (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2025 (%)
- Y-o-Y Growth Analysis, 2016 – 2025
- Region Trends
- Market Size and Forecast, By Country, 2017 and 2025 (%)
- KSA
- Country Trends *
- Market Size and Forecast (US$ Million)
- UAE
- Bahrain
- Oman
- Qatar
- Israel
- Iran
- KSA
- Introduction
- Competitive Landscape
- Company Profiles
- Section
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
